Evotec AG today announced a strategic alliance with Forge Therapeutics, Inc. („Forge“) to advance its novel Gram-negative antibiotic programme targeting „LpxC“ for the treatment of bacterial infections including those caused by drug resistant ’superbugs‘. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-forge-therapeutics-form-strategic-superbug-alliance-8